CA3111618A1 - Magnesium-containing formulation and uses thereof - Google Patents

Magnesium-containing formulation and uses thereof Download PDF

Info

Publication number
CA3111618A1
CA3111618A1 CA3111618A CA3111618A CA3111618A1 CA 3111618 A1 CA3111618 A1 CA 3111618A1 CA 3111618 A CA3111618 A CA 3111618A CA 3111618 A CA3111618 A CA 3111618A CA 3111618 A1 CA3111618 A1 CA 3111618A1
Authority
CA
Canada
Prior art keywords
formulation
magnesium
carnitine
source
range
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3111618A
Other languages
English (en)
French (fr)
Inventor
David ZELINKER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tudu Holdings Ltd
Original Assignee
Tudu Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tudu Holdings Ltd filed Critical Tudu Holdings Ltd
Publication of CA3111618A1 publication Critical patent/CA3111618A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3111618A 2018-09-06 2019-06-27 Magnesium-containing formulation and uses thereof Pending CA3111618A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL261670 2018-09-06
IL261670A IL261670B (en) 2018-09-06 2018-09-06 Magnesium-containing formulation and uses thereof
PCT/IL2019/050717 WO2020049549A1 (en) 2018-09-06 2019-06-27 Magnesium-containing formulation and uses thereof

Publications (1)

Publication Number Publication Date
CA3111618A1 true CA3111618A1 (en) 2020-03-12

Family

ID=63998430

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3111618A Pending CA3111618A1 (en) 2018-09-06 2019-06-27 Magnesium-containing formulation and uses thereof

Country Status (6)

Country Link
US (1) US20210322465A1 (cg-RX-API-DMAC10.html)
EP (1) EP3846779A4 (cg-RX-API-DMAC10.html)
JP (1) JP2021536494A (cg-RX-API-DMAC10.html)
CA (1) CA3111618A1 (cg-RX-API-DMAC10.html)
IL (1) IL261670B (cg-RX-API-DMAC10.html)
WO (1) WO2020049549A1 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020262703A1 (ja) * 2019-06-25 2020-12-30 独立行政法人国立病院機構 タキシフォリンを含有する肝線維化抑制剤及び褐色脂肪細胞活性化剤

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2018137C (en) * 1989-06-14 2000-01-11 Thomas Scholl L-carnitine magnesium citrate
IT1306130B1 (it) * 1999-04-16 2001-05-30 Sigma Tau Healthscience Spa Composizione comprendente una carnitina e glutatione, atta adaumentare l'assorbimento del glutatione sinergizzandone gli effetti.
WO2002041706A2 (en) * 2000-11-21 2002-05-30 Alpha Foods Ingredients, Inc. Bioactive compositions comprising conjugated linoleic acid glycerides and methods for producing bioactive conjugated linoleic acid
US6686340B2 (en) * 2001-06-19 2004-02-03 Matthias Rath Composition and method for prevention and treatment of health conditions caused by constriction of smooth muscle cells
US20050215640A1 (en) * 2004-03-26 2005-09-29 Baxter Jeffrey H HMB compositions and uses thereof
US20130236529A1 (en) * 2012-03-09 2013-09-12 Flavitpure, Inc. Composition and methods to enhance anti-oxidation, gut flora and immunity in pets
UA125747C2 (uk) * 2015-09-01 2022-06-01 Фьост Вейв Байо, Інк. Способи та композиції для лікування станів, пов'язаних із аномальною запальною відповіддю
EP3355989A4 (en) * 2015-10-02 2019-06-05 Balchem Corporation COMPOSITION WITH IMPROVED EFFICIENCY
KR101782134B1 (ko) * 2015-12-11 2017-09-26 (주) 머니키 카르시니아캄보지아 추출물을 함유한 건강보조식품
RU2629606C1 (ru) * 2016-08-01 2017-08-30 Федеральное государственное бюджетное образовательное учреждение высшего образования "Национальный исследовательский Мордовский государственный университет им. Н.П. Огарёва" Применение соединения магния, обладающего гепатопротекторной активностью, для лечения алкогольного и лекарственного гепатита

Also Published As

Publication number Publication date
JP2021536494A (ja) 2021-12-27
US20210322465A1 (en) 2021-10-21
WO2020049549A1 (en) 2020-03-12
IL261670B (en) 2019-06-30
IL261670A (en) 2018-10-31
EP3846779A4 (en) 2022-06-01
EP3846779A1 (en) 2021-07-14

Similar Documents

Publication Publication Date Title
US11773051B2 (en) S-enantiomers of beta-hydroxybutyrate and butanediol and methods for using same
US10588877B2 (en) Compositions comprising β-hydroxybutyric acid and salt, and methods of using the same
WO2020092451A1 (en) Administration of butyrate, bete-hydroxybutyrate, cannabidiol, and related compounds in humans
US12350243B2 (en) Compositions and compounds containing beta-hydroxybutyrate and one or more amino acids
US20160374381A1 (en) Nutritional Composition
US20100137226A1 (en) Fatigue-reducing agent
TW201417806A (zh) 用於改善兒童的線性生長反應之方法
US20250302782A1 (en) Administration of beta-hydroxybutyrate and related compounds in humans for the treatment and/or prevention of respiratory illnesses
CA2840363A1 (en) Compositions comprising a central nervous system stimulant and select micronutrients useful in the treatment of chronic fatigue
US9642825B2 (en) Bio-available N-acetyl creatine species and compositions thereof
US20120328695A1 (en) Compositions and methods for treatment of chronic fatigue
EP3846779A1 (en) Magnesium-containing formulation and uses thereof
AU2022212793A9 (en) Use of exogenous ketone esters to induce weight loss in mammals
US20230149329A1 (en) C5 ketone compositions and related methods for therapeutic and performance supplementation
WO2023211755A1 (en) C5 ketone compositions, and related methods, for therapeutic and performance supplementation
JP2018027923A (ja) ケトン体生成促進用組成物
US20250282707A1 (en) Novel ketone ester compounds
US20250367147A1 (en) Solid r-beta-hydroxybutyric acid composition
US12599579B2 (en) Compositions and compounds containing ketone bodies and/or ketone body precursors and one or more amino acids
US12496283B2 (en) Administration of R-beta-hydroxybutyrate and related compounds in humans
US12521378B2 (en) Administration of R-beta-hydroxybutyrate salt blend and related compounds in humans
US12171735B2 (en) Administration of butyrate, beta-hydroxybutyrate, cannabidiol, and related compounds in humans
US20240074996A1 (en) C5 ketone compositions and related methods for treating metabolic dysfunction
JP2008255087A (ja) 自発運動促進剤

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220830